The highest incidence of MH is in children10,11
Risk of MH events is 5 times higher in children10,11
- Children under the age of 15 years account for 52% of all MH reactions11
- Incidences of MH during anesthesia procedures are estimated at 1 in 10,000 for children compared with 1 in 50,000 for adults10
Severity of MH effects vary depending on child’s age
- A recent study revealed that there are age-based differences in acute MH characteristics across pediatric age groups12
- Older children (13 to 18 years of age) may have more severe effects of MH than younger children due to the significant periods of skeletal muscle growth during puberty12
Pediatric dosing for RYANODEX® requires significantly fewer vials and less sterile water for injection than other formulations1,5-7
| Patient weight Maximum cumulative dose (10 mg/kg)* |
Other formulations Vials needed (mL) |
RYANODEX® Vials needed (mL) |
|---|---|---|
| 5 kg (50 mg) | 3 vials (150 mL) | 1 vial (1 mL) |
| 10 kg (100 mg) | 5 vials (300 mL) | 1 vial (2 mL) |
| 50 kg (500 mg) | 25 vials (1500 mL) | 2 vials (10 mL) |
| 75 kg (750 mg) | 38 vials (2250 mL) | 3 vials (15 mL) |
| 100 kg (1000 mg) | 50 vials (3000 mL) | 4 vials (20 mL) |
With RYANODEX®, delivered via intravenous push, the total volume of fluid being administered is significantly lower compared with other formulations. Dosage increases are based on patient’s weight. Therefore, the number of vials reconstituted and administered also increases.1,6,7,13
*Labeled dose range of a minimum of 1 mg/kg up to a maximum cumulative dose of 10 mg/kg. If the physiologic and metabolic abnormalities of MH reappear, repeat RYANODEX® dosing by intravenous push starting with 1 mg/kg.